Aadi Bioscience, Inc. (AADI) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St futures fall as chip selloff gathers pace; Netflix tumbles
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
August 10, 2022 8:00 AM EDTFYARRO® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022
PRECISION 1 Phase 2 tumor-agnostic registration-directed trial continues enrollment and rapid site activation at major cancer centers and large community networks; preliminary data expected 1H23
Conference call to be held today at 8:30 am EDT
LOS ANGELES, Aug. 10, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for... More
